IP Library › Granted Patent US 10,034,887
Granted Patent B2
US 10,034,887 · App. 15/269,833 · Granted Jul 31, 2018

Compositions and methods for the treatment of meibomian gland dysfunction

Inventors: Yair Alster (Tel Aviv, IL); Omer Rafaeli (Udim, IL); K. Angela MacFarlane (Menlo Park, CA); Cary Reich (Santa Barbara, CA); Shimon Amselem (Rehovot, IL); Doron Friedman (Carme-Yosef, IL)
Assignee: M.G. THERAPEUTICS, LTD.
A61K31/60A61K8/23A61K9/0048A61K31/327A61K33/04A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,034,887
App. No.
15/269,833
Granted
Jul 31, 2018
Kind
B2
Abstract

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Claims (27)

1. A method for treating meibomian gland dysfunction in a patient in need thereof, comprising topically administering to the patient a composition that reaches the eyelid margin of the patient, wherein the composition comprises a therapeutically-effective amount of at least one keratolytic agent in an ophthalmically-acceptable carrier, wherein the keratolytic agent is salicylic acid and wherein the meibomian gland dysfunction is characterized by keratinized obstruction.

2. The method of claim 1 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 30%.

3. The method of claim 1 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 10%.

4. The method of claim 1 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 6%.

5. The method of claim 1 , wherein composition is topically administered to the patient until the keratinized obstruction is relieved.

6. The method of claim 1 , wherein composition is topically administered to the patient periodically after relieving the keratinized obstruction.

7. The method of claim 1 , wherein the topical administration is a single administration.

8. The method of claim 1 , wherein the topical administration is a periodic administration.

9. The method of claim 8 , wherein the periodic administration is once a day.

10. The method of claim 8 , wherein the periodic administration is two times a day.

11. The method of claim 1 , wherein the composition for topical administration is a semi-solid.

12. The method of claim 1 , wherein the composition for topical administration is homogenous.

13. The method of claim 1 , wherein the composition for topical administration is a dispersion.

14. The method of claim 1 , wherein the composition for topical administration is hydrophilic.

15. The method of claim 1 , wherein the composition for topical administration has an oleaginous base.

16. The method of claim 1 , wherein the ophthalmically-acceptable carrier comprises at least one ophthalmically-acceptable excipient.

17. The method of claim 1 , wherein the administration of the composition results in enhanced meibum production.

18. A method for treating meibomian gland dysfunction in a patient in need thereof, comprising topically administering to the patient a composition that reaches the eyelid margin of the patient, wherein the composition consists essentially of a therapeutically-effective amount of a keratolytic agent in an ophthalmically-acceptable carrier, wherein the keratolytic agent salicylic acid and wherein the meibomian gland dysfunction is characterized by keratinized obstruction.

19. The method of claim 18 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 30%.

20. The method of claim 18 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 10%.

21. The method of claim 18 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 6%.

22. The method of claim 18 , wherein the administration of the composition results in enhanced meibum production.

23. The method of claim 18 , wherein the composition for topical administration is homogenous.

24. The method of claim 18 , wherein the composition for topical administration is a dispersion.

25. The method of claim 18 , wherein the composition for topical administration is hydrophilic.

26. The method of claim 18 , wherein the composition for topical administration has an oleaginous base.

27. The method of claim 18 , wherein the ophthalmically-acceptable carrier comprises at least one ophthalmically-acceptable excipient.

Assignments (2)
CHANGE OF NAME Recorded Jan 23, 2020
From: M.G. THERAPEUTICS LTD
To: AZURA OPHTHALMICS LTD
Reel/Frame 051602/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: ALSTER, YAIR; RAFAELI, OMER; MACFARLANE, KIRSTEN ANGELA; REICH, CARY; AMSELEM, SHIMON; FRIEDMAN, DORON
To: M.G. THERAPEUTICS, LTD.
Reel/Frame 040086/0961 →
Continuity (3)
Continuation 14732622 · Jun 5, 2015
Provisional Application 62065716 · Oct 19, 2014
Related Publication 20170035785A1 · Feb 9, 2017
Cited By (4)
US 12,427,158 US 12,447,162 US 12,458,661 US 12,697,352